6-bromo-2-methoxy-4-(5-chloro-thiophen-2-yl)-quinoline | 594818-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-bromo-2-methoxy-4-(5-chloro-thiophen-2-yl)-quinoline
• 英文别名: 6-Bromo-4-(5-chlorothiophen-2-yl)-2-methoxyquinoline
• CAS: 594818-59-4
• 化学式: C₁₄H₉BrClNOS
• 分子量: 354.655
• InChiKey: NBQUGRNVZCHYJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  50.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-bromo-2-methoxy-4-(5-chloro-thiophen-2-yl)-quinoline 以 6-bromo-2-methoxy-4-(5-methyl-thiophen-2-yl)-quinoline 为溶剂， 以54%的产率得到(4-chloro-phenyl)-[2-methoxy-4-(5-chloro-thiophen-2-yl)-quinolin-6-yl]-(3-methyl-3H-imidazol-4-yl)-methanol
  参考文献：
  名称：

  US2003/166675

  摘要：

  公开号：
• 作为产物：
  描述：

  6-bromo-4-(5-chloro-thiophen-2-yl)-1H-quinolin-2-one 以 6-bromo-4-(5-methyl-thiophen-2-yl)-1H-quinolin-2-one 为溶剂， 生成 6-bromo-2-methoxy-4-(5-chloro-thiophen-2-yl)-quinoline
  参考文献：
  名称：

  US2003/166675

  摘要：

  公开号：

文献信息

• Substituted quinolin-2-one derivatives useful as antiproliferative agents
  申请人：——

  公开号：US20030166675A1

  公开（公告）日：2003-09-04

  The present invention relates to compounds of formulas 1 and 2 1 wherein R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , R 10 and Z are as defined herein. The present invention also relates to pharmaceutical compositions containing the above compounds and to methods of treating hyperproliferative disorders, such as cancer, in a mammal by administering the above compounds.

  本发明涉及式1和21的化合物，其中R1，R2，R4，R5，R6，R7，R8，R10和Z的定义如本文所述。本发明还涉及含有上述化合物的制药组合物，以及通过给哺乳动物施用上述化合物治疗增殖性疾病，如癌症的方法。
• Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
  申请人：Lalji Karim

  公开号：US20050176680A1

  公开（公告）日：2005-08-11

  One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT 2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT 2A modulator or DRI.
• US6844357B2
  申请人：——

  公开号：US6844357B2

  公开（公告）日：2005-01-18